Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Monopar Therapeutics Inc ( (MNPR) ) has shared an update.
Monopar Therapeutics Inc. announced promising early results from its MNPR-101-Zr Phase 1 clinical trial, showcasing the compound’s ability to specifically target tumors in cancer patients. The trial’s positive outcomes, based on PET imaging, validate the targeted approach of MNPR-101-Zr, a humanized monoclonal antibody, against cancers with high expression of the urokinase plasminogen activator receptor, such as triple-negative breast, colorectal, and pancreatic cancers. These findings pave the way for future therapeutic developments, with additional data set to be presented at a prestigious medical congress.
See more data about MNPR stock on TipRanks’ Stock Analysis page.
